Aripiprazole reduces severity of tics in children with Tourette's disorder


New Rochelle, NY, July 20, 2016–A meta-analysis of clinical trials evaluating the effectiveness of aripiprazole for the treatment of Tourette's disorder (TD) in children and adolescents showed a significantly greater overall improvement in total tics and tic severity from pretreatment to post-treatment for the aripiprazole compared to the placebo group. The drug was safe, with drowsiness, nausea, and headache being the most common adverse effects, according to the study published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Child and Adolescent Psychopharmacology website until August 20, 2016.

The article "Effectiveness and Tolerability of Aripiprazole in Children and Adolescents with Tourette's Disorder: A Meta-Analysis" describes an assessment of ten studies that included 302 patients with a mean age of 11.6 years. Coauthors Yueying Liu, MD and Chunhong Wang, MD, Jiangnan University (Wuxi), Hong Ni, MD and Lili Li, MD, Soochow University Affiliated Children's Hospital (Suzhou), Zaohuo Chen, MD, Nanjing Medical University (Wuxi), and Zhen Weng, PhD, Chinese Academy of Sciences (Suzhou), China, report on the therapeutic potential of aripiprazole, an atypical antipsychotic drug, for treating TD in a pediatric population.

"Treatment of children with Tourette's remains challenging for many clinicians. This study highlights the effectiveness of aripiprazole for this group of patients," says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.


About the Journal

Journal of Child and Adolescent Psychopharmacology is an authoritative peer-reviewed journal published ten times per year online with open access options and in print. The Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology. Complete tables of content and a sample issue may be viewed on the Journal of Child and Adolescent Psychopharmacology website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cyberpsychology, Behavior, and Social Networking, Games for Health Journal, and Violence and Gender. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in itss field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Media Contact

Kathryn Ryan
[email protected]